The N9xxxx series of GSNOR inhibitors have been specifically designed for high oral bioavailability. Pre-clinical testing has shown them to have a high margin of safety as well as efficacy in smoking models for lung disease.
The N9xxxx series is particularly attractive as candidate therapies for inflammatory lung diseases such as COPD and asthma.